Navigation Links
A budding role for a cellular dynamo
Date:2/18/2009

Waltham, MAActin, a globular protein found in all eukaryotic cells, is a workhorse that varies remarkably little from baker's yeast to the human body. Part of the cytoskeleton, actin assembles into networks of filaments that give the cell structural plasticity while driving many essential functions, from cell motility and division, to vesicle and organelle transport within the cell. In a groundbreaking new study in the current issue of Developmental Cell, Brandeis researchers raise the curtain on how this actin maintains just the right filament length to keep the cell healthy and happily dividing.

Using baker's yeast as the model organism, Brandeis researchers Melissa Chesarone, Christopher Gould, and James Moseley, all in the lab of biologist Bruce Goode, set out to discover how the length of actin fibers is controlled. By answering this question, the scientists sought to advance understanding of asymmetrical cell division, a process that not only allows yeast to divide, but also ensures the proper renewal of human stem cells and plays a crucial role in early stages of embryonic development.

In yeast cells, as in all other cells, actin fibers serve as internal "railways" or tracks that give the cell directionality and provide the wherewithal for transporting various molecular and membrane-bound cargoes from one end of the cell to the other. Molecular machines called formins produce many of the actin fibers, but in the absence of a displacement factor to put a brake on the process, formins will essentially stop at nothing, producing excessively long actin filaments at ridiculously fast rates, and wreaking cellular havoc, says Goode. In humans, genetic defects in formins are associated with conditions such as infertility and deafness.

"We wanted to know how you turn the formins off. What disrupts the interaction of the formin with the actin filament, thus terminating actin assembly and regulating its length?" Goode explained.'/>"/>

Contact: Laura Gardner
gardner@brandeis.edu
781-736-4204
Brandeis University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Tuning in on cellular communication in the fruit fly
2. Researchers identify new function of protein in cellular respiration
3. Dictyostelium cells shown to lay breadcrumb trail as first step in multicellular formation
4. Johns Hopkins researchers detect sweet cacophony while listening to cellular cross-talk
5. Columbia to award 2008 Horwitz Prize to Arthur Horwich & Ulrich Hartl for cellular protein folding
6. UC San Diego bioengineers fill holes in science of cellular self-organization
7. A new cellular pathway linked to cancer is identified by NYU researchers
8. Cellular self-eating promotes pancreatitis
9. LIAI researchers discover new cellular mechanism that will significantly advance vaccine development
10. Researchers discover critical detail of cellular defense against genetic mistakes
11. Genome of marine organism tells of humans unicellular ancestors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... CORVALLIS, Ore. According to an analysis of statewide ... less than $50,000 a year were more than three ... health providers because of their insurance status during pregnancy ... discrimination was also three times more likely among mothers ...
(Date:12/4/2009)... Royal Botanic Gardens, Kew and the Natural History Museum ... widespread than previously thought, with many commonly grown plants ... to being "meat eaters". A review paper, Murderous plants: ... is published today (4 December 2009) in the ...
(Date:12/4/2009)... is available in German . , A ... Ageing could help to understand the positive effect of dietary ... flies and mice) have shown that dietary restriction increases longevity, ... So the female fruit fly reproduces less frequently with a ...
Breaking Biology News(10 mins):Lower income women report more insurance-based discrimination during pregnancy, delivery 2Scientists think 'killer petunias' should join the ranks of carnivorous plants 2How nutrition affects healthy aging 2Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 1Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 2Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 3Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 4Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 5Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 6Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 7Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 8Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 9Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 10Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 11Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 12Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 13Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 14Webcast Alert 3A Usinas Siderurgicas de Minas Gerais S A USIMINAS Announces Third Quarter 2009 Results Webcast 59442 1Webcast Alert 3A Usinas Siderurgicas de Minas Gerais S A USIMINAS Announces Third Quarter 2009 Results Webcast 59442 2Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 1Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 2Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 3Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 4Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 5Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 6Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 7Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 8
... responsible for the single most common cause of hearing ... the first time, a scientist told the annual conference ... France. Ms Melissa Thys, from the Department of Medical ... may be a step towards new treatments for otosclerosis, ...
... nanoparticle made in a laboratory at the University of ... device for treating glaucoma, an eye disease that can ... “The nanoparticle can safely get past the blood-brain barrier ... said Sudipta Seal, an engineering professor with appointments in ...
... announced this week the discovery of a mechanism by ... in serious lung infections and is prevalent in emphysema ... or “macrophages” and thus compromises the body’s immunity. , ... State University, will be published online this week in ...
Other Biology News:Gene responsible for common hearing loss identified for first time 2UCF nanoparticle offers promise for treating glaucoma 2Researchers discover 'acquired' DNA key to certain bacterial infection 2
(Date:12/2/2009)... NEW YORK, Dec. 2 Nearly 600 medical research ... explore novel development approaches and innovative funding strategies at ... ,, FasterCures, the Washington-based center of the ... facilitate multi-sector collaborations needed to turn a scientific discovery ...
(Date:12/2/2009)... , - "Bolstering ... Coinciding with the International ... is hosting an international conference in Libreville,(Gabon) on ... The,conference will be attended by government and state ...
(Date:12/2/2009)... announced data presentations on its novel oral JAK2 inhibitor, ... Meeting and Exposition in New Orleans. ,, Data will ... 1 dose-escalation trial of SB1518 detailing its safety, tolerability ... 100 to 600 mg. These doses were administered once ...
(Date:12/2/2009)... SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going ... part of many,businesses and industries. It turns out that ... downturn, because illness doesn,t take a,vacation. , ... this year, the pharmaceutical,giant Johnson & Johnson inaugurated an ...
Breaking Biology Technology:Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3
... Inc.,(Nasdaq: SUPG ), a pharmaceutical company dedicated ... for solid tumors and,hematological malignancies, today announced that ... is scheduled to present at the Thomas,Weisel Partners ... Four,Seasons Hotel in Boston. SuperGen,s presentation at ...
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) a biopharmaceutical ... candidates for the treatment,of cancer and infectious diseases, ... officer, is scheduled to present at the 2007,Thomas ... at 1:30 p.m. Eastern Daylight Time. The conference ...
... 28 DOV Pharmaceutical,Inc. ("DOV" or the "Company") (OTC ... common stock is now being quoted on the OTC,Bulletin ... also still,being quoted on the Pink Sheets. "We ... now being quoted,both on the OTC Bulletin Board and ...
Other Biology Technology:ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference 2DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board 2
F40 piston seals are supplied as 2 seals with a seal tool to service one F40 pump of a BioLogic DuoFlow workstation....
... This depletion cocktail is ... (CD3+CD4+CD8+) cells from suspensions of ... Cells are separated using the ... immunomagnetic negative selection system, achieving ...
...
... This depletion cocktail is tailored ... cells from suspensions of non-human ... are separated using the StemSep ... selection system. The CD4+ T ...
Biology Products: